Tag Archives: Jardiance

Thank you, Jardiance: Diabetes drug sales ease Boehringer’s patent-loss pain

As sales of its blockbuster asthma and COPD drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from its other products. Turns out diabetes was the key. The German drugmaker reported an impressive 52.5% increase in sales from its partnership with Eli Lilly on the Jardiance family of SGLT2 diabetes drugs, including Synjardi and… Read More »